NEWBURGH, Ind (WEHT) Deaconess announced that on Friday, they received 180 doses of a new antibody to treat COVID-19. The Eli Lilly drug bamlanivimab received emergency use authorization from the FDA last week.
BAM is for treating mild to moderate COVID-19 patients who are considered to be high risk of progressing to severe COVID-19 or needing hospitalization.
The treatment is only available through infusion, and Deaconess can treat up to 33 patients a day. Hospital officials are hopeful it will reduce hospitalization numbers and save lives.
More information about bamlanivimab can be found here.
(This story was originally published on November 16, 2020)
LATEST LOCAL NEWS: